Gateway Care And Retirement Medicare and Medicaid Location: 39 Ne 102nd Avenue, Portland, Oregon 97220 Ratings: Phone: (503) 252-2461 |
Mirabella Portland Medicare Location: 3550 Sw Bond Ave, Portland, Oregon 97239 Ratings: Phone: (503) 245-4742 |
Creekside Rehabilitation And Nursing Medicare and Medicaid Location: 812 Se 48th Avenue, Portland, Oregon 97215 Ratings: Phone: (503) 236-2624 |
Providence Child Center Medicaid Location: 830 Ne 47th Avenue, Portland, Oregon 97213 Ratings: Phone: (503) 215-2400 |
Marquis Autumn Hills Memory Care Medicaid Location: 6630 Sw Beaverton-hillsdale Hwy, Portland, Oregon 97225 Ratings: Phone: (503) 292-7874 |
Rose Villa Senior Living Community Medicaid Location: 13505 Se River Road, Portland, Oregon 97222 Ratings: Phone: (503) 654-3171 |
Cedar Crossings Medicaid Location: 6003 Se 136th Avenue, Portland, Oregon 97236 Ratings:NA Phone: (503) 761-1155 |
East Portland Care Center Medicaid Location: 34 Ne 20th Avenue, Portland, Oregon 97232 Ratings: Phone: (503) 231-0276 |
Cornerstone Care Option Medicaid Location: 12640 Se Bush, Portland, Oregon 97236 Ratings: Phone: (503) 761-6621 |
Gracelen Terrace Nf Medicaid Location: 10948 S.e. Boise, Portland, Oregon 97266 Ratings: Phone: (503) 760-1727 |
News Archive
A new study shows that susceptibility-weighted imaging is a powerful tool for characterizing infarctions in patients earlier and directing more prompt treatment.
The Allen Institute for Cell Science today launched the first predictive and comprehensive, 3D model of a live human cell, the Allen Integrated Cell.
Researchers at the University of California, San Diego have received a five-year, $3 million grant from the Eunice Kennedy Shriver Institute of Child Health and Human Development, part of the National Institutes of Health (NIH).
Health and Human Services Secretary Kathleen Sebelius is resigning from the Obama administration after the rocky rollout of President Barack Obama's signature health care law, a White House official said Thursday.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma.
› Verified 4 days ago